Journal of Clinical Laboratory Analysis · 2022 · 16 citations · 22 references
MedicineImmunologyOncologyMolecular OncologyTumor ImmunologyTumor MicroenvironmentCancer GenomicsCancer Molecular PathologyCancer TranscriptomicsMalignant NeoplasmsMolecular Tumor ProfilingTumor ClassificationImmune Gene Expression SignaturesImmune Infiltration BiomarkersImmune Landscape ProfilingImmune Microenvironment PrognosisPrognostic Gene SignaturesTumor Immune Microenvironment ProfilingTumor Microenvironment CharacterizationTumor Mutational Burden Assessment
BACKGROUND: Cuproptosis is considered a novel copper-dependent cell death model. In this study, we established a novel scoring system based on 10 cuproptosis-related genes (CRGs) to predict the prognosis and immune landscape of head and neck squamous cell carcinoma (HNSCC). METHODS: The RNA-seq data of HNSCC patients were downloaded from the GEO and TCGA databases and were merged into a novel HNSCC cohort. Multiomics landscape analyses were conducted, including tumor mutation burden (TMB), copy number variations and the interaction network of CRGs. Patients were then divided into different cuproptosis subtypes based on the expression of 10 CRGs and subsequently regrouped into novel gene clusters referring to differentially expressed genes. A cuproptosis score (CS) system was established using principal component analysis. The CIBERSORT, ssGSEA and ESTIMATE algorithms were used to assess the tumor immune microenvironment. Moreover, the immunotherapeutic and chemotherapeutic responses were assessed. RESULTS: Patients were divided into three cuproptosis subtypes and subsequently regrouped into three gene clusters, reflecting different immune infiltration. Assessed by the CS system, those with higher CSs exhibited worse prognosis and higher TMB frequency. Nevertheless, the immune-related analysis revealed patients in the low-CS group appeared immunosuppressive and easily suffered from immune escape. High CSs possibly show high expression of immune checkpoint genes and enhance chemotherapy sensitivity to cisplatin, docetaxel, and gemcitabine. CONCLUSION: We established a novel scoring system to predict the prognosis and immune landscape of HNSCC patients. This signature exhibits satisfactory predictive effects and the potential to guide comprehensive treatment for patients.
22
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang, Shengqing Gu, Deng Pan et al. · Nature Medicine · 2018 · 5.6K citations · Full text
Life Sciences, Immunology, Oncology +14
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Copper induces cell death by targeting lipoylated TCA cycle proteins
Peter Tsvetkov, Shannon Coy, Boryana Petrova et al. · Science · 2022 · 4.7K citations · Full text